---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-073084"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:03:50.025235+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA CMO resigns; Schlienger and Necina promoted effective July 1

## Summary
- CMO Igor Matushansky resigns effective June 30, 2022; will chair Scientific Advisory Board.
- Katia Schlienger promoted to EVP Clinical Development, joins Executive Team.
- Roman Necina appointed Chief Development Officer, integrating manufacturing and project management.
- Gilead registration rights agreement filed; Gilead may purchase up to $35M in common stock; initial $5M at $3.00/share.

## SEC filing metadata
- accession: 0001104659-22-073084
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/tm2218404d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-073084
- JSON: https://secwatch.observer/filing/0001104659-22-073084.json
- Plain text: https://secwatch.observer/filing/0001104659-22-073084.txt

## Key facts
- Executive change
  Igor Matushansky was appointed as Chair of Scientific Advisory Committee at HOOKIPA Pharma Inc..
  - Action: appointed
  - Role: Chair of Scientific Advisory Committee
  source text: Dr. Matushansky was also appointed to chair the Company’s newly formed Scientific Advisory Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm
- Executive change
  Igor Matushansky resigned as Chief Medical Officer and Global Head of Research and Development at HOOKIPA Pharma Inc..
  - Action: resigned
  - Role: Chief Medical Officer and Global Head of Research and Development
  source text: On June 20, 2022, Igor Matushansky, M.D., Ph.D., who has served as the Chief Medical Officer and Global Head of Research and Development of the Company, notified the Company that he will resign from his current positions, effective as of June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/0001104659-22-073084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.